Tag:

Genentech

Latest Headlines

Latest Headlines

Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe

The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.

Celgene, Genentech back clinical trial enrollment challenge

Celgene and Genentech are funding a clinical trial innovation prize focused on doubling the rate of participation in studies of cancer drugs. The project is challenging the crowd to submit ideas and evidence of their effectiveness in return for the chance to land a piece of the $75,000 prize kitty.

Roche's Genentech investing $125M in Oregon plant

With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.

Genentech project to add 100 jobs

Roche's Genentech subsidiary is embarking on a $125 million project that will take Roche's investment in biologics production to over $1 billion and add 100 more jobs to the 500 Roche initially said its biologics expansion would create.

San Francisco requires drugmakers to fund disposal of unused meds

California's Alameda County has held fast against Big Pharma pushback to its drug take-back ordinance that requires drugmakers to fund a program for accepting and destroying unused meds. Now San Francisco has passed its own ordinance to require the same thing.

Genentech: Hospitals aren't telling us about distribution-related treatment delays

Genentech begs to differ with a survey finding that its new distribution method is delaying treatment for some cancer patients. Hospitals may be complaining in press releases about the change to Herceptin, Rituxan and Avastin purchasing, but they're not reporting particular treatment problems to the company, Genentech says.

Chronic disease therapies dominate top-selling drugs in Taiwan

Seventy percent of the 20 best-selling drugs in Taiwan are for treating blood pressure, strokes and other chronic diseases.

Hospitals say Roche supply chain move is affecting patient care

Hospitals continue to pressure Roche's Genentech to stop using specialty distributors for some of its cancer meds. The latest move is a survey in which not only do respondents claim the change is costing them money, but more than a quarter said it is delaying patient care, The Wall Street Journal blog Pharmalot reports.

Genentech's cancer drug supply switch costs more, delays treatment, survey finds

Top hospitals are still irate about Genentech's decision to move its best-selling cancer drugs to specialty distributors. And they're not giving up on persuading the company to change back.

PARI snags FDA approval for cystic fibrosis nebulizer platform

Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme.